购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 货期 筛选
  • 现货
    (5)
  • 5日内发货
    (3)
  • 35日内发货
    (3)
  • 6-8周
    (1)
TargetMol | Tags 通过 靶点 筛选
  • Antibacterial
    (1)
  • Antifungal
    (1)
  • Reactive Oxygen Species
    (1)
  • STAT
    (1)
筛选
搜索结果
TargetMol产品目录中 "

luciferase-in-1

"的结果
  • 抑制剂&激动剂
    10
    TargetMol | Inhibitors_Agonists
  • 重组蛋白
    2
    TargetMol | Recombinant_Protein
  • 染料试剂
    5
    TargetMol | Dye_Reagents
Luciferase-IN-1
荧光素酶-IN-1
T3831010205-56-8
Luciferase-IN-1 是一种荧光素酶抑制剂,可用于研究细菌感染和真菌感染。
  • ¥ 245
现货
规格
数量
Firefly luciferase-IN-1
T99432765796-41-4
Firefly luciferase-IN-1 是一种 2-亚苄基四氢萘酮衍生物,可在试剂盒中用作萤火虫荧光素酶抑制剂。
  • ¥ 1070
现货
规格
数量
TargetMol | Inhibitor Sale
STAT6-IN-2
T791851355594-85-2
STAT6-IN-2(R)-84 是一种 STAT6 抑制剂,抑制 eotaxin-3 的分泌,抑制 293-EBNA 细胞中诱导 STAT6 报告荧光素酶活性,抑制 STAT6 的酪氨酸磷酸化。
  • ¥ 736
现货
规格
数量
MEISi-1
T69241446306-43-0
MEISi-1 is a novel MEIS inhibitor (MEISi), significantly inhibiting MEIS-luciferase reporters in vitro and inducing murine (LSKCD34low cells) and human (CD34+, CD133+, and ALDHhi cells) HSC self-renewal ex vivo.
  • ¥ 10600
6-8周
规格
数量
N-(1-(3,4-Dihydroxyphenyl)propan-2-yl)oleamide
T382231258011-97-0
N-(1-(3,4-Dihydroxyphenyl)propan-2-yl)oleamide binds to the cannabinoid 1 (CB1) receptor with a Ki value of 365 nM in a radioligand binding assay using rat brain homogenate. It has an EC50 value of 698 nM for the peroxisome proliferator-activated receptor α (PPARα) in a luciferase reporter assay and, in rats, it decreases food intake. It does not inhibit fatty acid amide hydrolase (FAAH).
  • ¥ 647
35日内发货
规格
数量
2-Bromo-1-decanal
Decanal-1-14C, 2-bromo-, (R)-, 2-Bromo(1-14C)-1-decanal
T2933693245-72-8
2-Bromo-1-decanal was synthesized as an affinity labeling probe for the aliphatic aldehyde site of Vibrio harveyi luciferase. In the presence of excess amounts of this probe, the inactivation of bacterial luciferase occurred following apparent first order
  • 询价
规格
数量
AZ0108
T701381825345-52-5
AZ0108 is an orally bioavailable, potent PARP1,2,6 inhibitor that potently inhibits centrosome clustering and is suitable for in vivo efficacy and tolerability studies. AZ0108 has been utilized as in vitro tools and in vivo probes to investigate the biological consequences of inhibiting centrosome clustering through PARP enzymes. AZ0108 is more selective in its enzyme inhibition profile and effects on cellular pathways and phenotypes. Specifically, AZ0108 inhibits PARPs 1, 2, and 6 with approximately 100-fold selectivity against PARP3 and TNKS1. Consistent with this lack of potencytowards tankyrase, AZ0108 is not active in a DLD-1 Wnt luciferase reporter assay.
  • ¥ 22700
10-14周
规格
数量
GW841819X
GW841819X
T36574
GW841819X is an analogue of (+)-JQ1 and a novel inhibitor of BET bromodomains. GW841819X was a single enantiomer but of undefined chirality at the 4-position of the benzodiazepine ring3. GW841819X and JQ1 were recently discovered that bind to the acetyl-lysine binding pocket of BET bromodomains with Kd ranges from 50 to 370 nM [1]. GW841819X bounded to both the individual BD1 and BD2 domains with affinities of 46 and 52.5 nM, respectively. GW841819X-Brd3 interaction was estimated to be around 70 nM4. GW841819X displayed activity in vivo against NUT-midline carcinoma, multiple myeloma, mixed-lineage leukemia, and acute myeloid leukemia1. It also potent induced the ApoA1 reporter gene with an EC50 of 440 nM. It had very little effect on LDL-R luciferase activity at the concentrations at which it induces ApoA1 expression, suggesting that the effect is indeed specific3. GW841819X competed directly with GATA1 site for BD1 binding and also specifically blocked the interaction between Brd3 and acetylated GATA14. Recent findings reported that GW841819X are chose as an interest compound to further develop into potential drugs against diseases including cancer, HIV infection and heart disease2.
  • ¥ 4768
期货
规格
数量
20-HEPE
T37092116477-57-7
20-HEPE is a metabolite of eicosapentaenoic acid that is formed via ω-oxidation of EPA by cytochrome P450 (CYP) ω-oxidases, including human CYP4F3B. It activates peroxisome proliferator-activated receptor α (PPARα) in COS-7 cells expressing a luciferase reporter when used at a concentration of 10 μM. 20-HEPE also activates murine transient receptor potential vanilloid receptor 1 (mTRPV1) in vitro but lacks antinociceptive activity in rats.
  • ¥ 4550
35日内发货
规格
数量
MD001
T358002254605-76-8
MD001 is a dual agonist of peroxisome proliferator-activated receptor α (PPARα) and PPARγ.1 It binds to PPARα and PPARγ (Kds = 9.55 and 0.14 μM, respectively) but does not bind to PPARβ/δ at concentrations up to 500 μM. It increases transcriptional activity of PPARα and PPARγ in a cell-based luciferase reporter assay when used at a concentration of 10 μM. MD001 (10 μM) increases expression of PPARα, PPARγ, and retinoid X receptor (RXR), as well as PPARα and PPARγ target genes, in HepG2 cells. It increases glucose consumption as well as expression of GLUT2 and GLUT4 in HepG2 and 3T3-L1 cells, respectively, in a concentration-dependent manner. MD001 (20 mg/kg) decreases levels of glucose, insulin, free fatty acids, triglycerides, LDL, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in blood and reduces the size and number of hepatic lipid droplets in diabetic db/db mice.References1. Kim, S.-H., Hong, S.H., Park, Y.-J., et al. MD001, a novel peroxisome proliferator-activated receptor α/γ agonist, improves glucose and lipid metabolism. Sci. Rep. 9(1), 1656 (2019). MD001 is a dual agonist of peroxisome proliferator-activated receptor α (PPARα) and PPARγ.1 It binds to PPARα and PPARγ (Kds = 9.55 and 0.14 μM, respectively) but does not bind to PPARβ/δ at concentrations up to 500 μM. It increases transcriptional activity of PPARα and PPARγ in a cell-based luciferase reporter assay when used at a concentration of 10 μM. MD001 (10 μM) increases expression of PPARα, PPARγ, and retinoid X receptor (RXR), as well as PPARα and PPARγ target genes, in HepG2 cells. It increases glucose consumption as well as expression of GLUT2 and GLUT4 in HepG2 and 3T3-L1 cells, respectively, in a concentration-dependent manner. MD001 (20 mg/kg) decreases levels of glucose, insulin, free fatty acids, triglycerides, LDL, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in blood and reduces the size and number of hepatic lipid droplets in diabetic db/db mice. References1. Kim, S.-H., Hong, S.H., Park, Y.-J., et al. MD001, a novel peroxisome proliferator-activated receptor α/γ agonist, improves glucose and lipid metabolism. Sci. Rep. 9(1), 1656 (2019).
  • ¥ 7610
35日内发货
规格
数量